Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study
-
Narrado por:
-
De:
Acerca de esta escucha
Within the EMPRISE® monitoring program, the cardiovascular effectiveness of empagliflozin (EMPA) vs. glucagon-like peptide-1 receptor agonists (GLP1RA) or liraglutide were evaluated. The patients ≥18 years with type 2 diabetes initiating (i) EMPA vs. GLP1-RA or (ii) EMPA vs. liraglutide were identified. Primary outcomes were hospitalization for heart failure (HHF), myocardial infarction (MI), stroke, and all-cause mortality.
Relative to GLP1RA, EMPA had a lower risk of hospitalization for heart failure, and a similar risk of myocardial infarction, stroke, and mortality. Patients with and without CVD had similar outcomes. Estimates from EMPA vs. liraglutide, both overall and across subgroups, were similar to those from GLP1 RA.
When compared to GLP-1RA or liraglutide, EMPA was linked with a lower risk of hospitalization for heart failure but a similar risk of myocardial infarction, stroke, and death throughout the CVD spectrum in real-world patients.